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Abstract
Purpose: The added value of baseline positron emission tomography (PET) scans in therapy
evaluation in malignant lymphoma is unclear. In guidelines, baseline PET is recommended but
not mandatory except in lymphoma types with variable fluoro-D-glucose uptake. The aim of the
present study was to test the hypothesis that adding baseline PET information decreases false
positive readings with posttreatment PET and improves observer agreement.
Methods: Forty-four patients (mean age 56 years, standard deviation 14) with malignant lymphoma
were included. Two nuclear medicine physicians retrospectively and independently evaluated the
posttreatment PET, 3 weeks later followed by paired reading of baseline and posttreatment PET.
For each PET, 22 regions were classified as positive, negative, or equivocal, resulting in an overall
PET score of positive, unclear, or negative. In case of discrepancies, consensus was reached.
Results: Addition of baseline to posttreatment PET evaluation affected the classification of
metabolic response in 34% of malignant lymphoma patients treated with first-line chemotherapy. In
one out of seven patients, addition of the baseline PET lead to opposite conclusions (95%
confidence interval 4–14). False positivity was reduced by adding the baseline scan information, but
the effect on false negativity was similar. In addition, the amount of unclear classifications halved
after paired reading. Observer agreement did not improve upon adding the baseline PET data.
Conclusion: Without any other clinical information, pretreatment PET facilitates changes the
interpretation of a posttreatment PET in a third of the patients, resulting in both upgrading and
downgrading of the posttreatment situation of a malignant lymphoma patient. If these results are
confirmed for PET–computed tomography systems, they favor the addition of baseline PET to
the current work-up of patients with malignant lymphoma.
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Introduction
Prognosis and survival of patients with Hodgkin’s disease(HD) and non-Hodgkin’s lymphoma (NHL) depend on
both histological grade and clinical stage at the moment of
diagnosis and furthermore on the response to treatment [1].
The Ann Arbor classification with Cotswolds revision is the
guideline for radiological staging of HD and most types of
NHL [2, 3]. In the past, the Ann Arbor staging system was
based on physical examination and bone marrow evaluation,
later to include the computed tomography (CT) scan. With the
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implementation of the positron emission tomography (PET)
scan and later the integrated PET/CT scan, several studies
concluded that a baseline 2-deoxy-2-[18F]fluoro-D-glucose
(FDG) PET scan provides significant more information than
conventional CT, with subsequent therapeutic consequences
[4–6]. Whereas the application of PET in therapy evaluation in
malignant lymphoma is rapidly emerging, the added value of
baseline PET scans in this context is less clear. In guidelines,
baseline PET is recommended but not mandatory except in
lymphoma types with variable FDG uptake. Baseline scans
may facilitate interpretation of PET at therapy evaluation,
increase reader confidence, and perhaps avoid misinterpreta-
tion. Guidelines on PET reading after therapy refer to
“previously involved lesions” to avoid false positivity [7–9].
The aim of the present study was to test the hypothesis that
adding baseline PET information decreases false positive
readings with therapy evaluation PET and improves observer
agreement.
Materials and Methods
Subjects
We retrospectively studied baseline and posttreatment PET scans of 44
patients with newly diagnosed malignant lymphoma undergoing first-
line therapy between January 2005 and July 2007. In all patients,
malignant lymphoma had been histopathologically proven, and initial
staging was done according to the Ann Arbor classification (with
supplementary baseline PET scan). The posttreatment PET scan was
performed at least 4–6 weeks after completion of therapy, and patients
were at least 10 days off granulocyte colony-stimulating factor (G-
CSF) therapy [7, 10]. The study was approved by the ethical board,
and informed consent was waived.
PET Imaging
PET was performed with a mobile scanner (ECAT-ACCEL,
Siemens/CTI, Knoxville, TN, USA). Patients fasted for 6 h before
the scan. Prior to injection, blood glucose levels were within the
normal range (G11 mmol/L). One hour after injection of FDG
(5 MBq/kg body weight), patients were scanned from mid femur to
Table 1. Patient characteristics of NHL and HD patients
Patient NHL HD
Number 35 9
M:F 16:19 7:2
Mean age (years; range) 58 (24–87) 40 (19–71)
Pathological subtypes DLBCL, 18 Nodular sclerosis, 7
Follicular, 9 Mixed cellularity, 2
Burkitt, 1
MCL, 2
MZL, 1
MALT, 1
SLL, 2
ACL, 1
NHL non-Hodgkin’s lymphoma, HD Hodgkin’s disease, M male, F female,
DLBCL diffuse large B cell lymphoma, MCL mantle cell lymphoma, MZL
marginal zone lymphoma, MALT mucosa-associated lymphoid tissue, SLL
small lymphocytic lymphoma, ACL anaplastic cell lymphoma
Table 2. Agreement of isolated posttreatment and reference PET classification (a), as a function of PET positivity criteria (b), and observer agreement (c)
(a)
Consensus-isolated posttreatment PET Consensus-paired reading (reference standard)
Negative Unclear Positive Total
Negative 19 2 3 24
Unclear 3 0 3 6
Positive 3 1 10 14
Total 25 3 16 44
(b)
Conservative: consensus-isolated posttreatment PET Conservative: consensus-paired reading (reference standard)
Negative Positive Total
Negative 24 6 30
Positive 4 10 14
Total 28 16 44
Sensitive: consensus-isolated posttreatment PET Sensitive: consensus-paired reading (reference standard)
Negative Positive Total
Negative 19 5 24
Positive 6 14 20
Total 25 19 44
(c)
Observer 1 isolated posttreatment PET Observer 1 posttreatment PET (paired reading)
Negative Unclear Positive Total
Negative 20 0 3 23
Unclear 4 1 2 7
Positive 4 2 8 14
Total 28 3 13 44
Observer 2 isolated posttreatment PET Observer 2 posttreatment PET (paired reading)
Negative Unclear Positive Total
Negative 17 2 2 21
Unclear 5 1 3 9
Positive 0 3 11 14
Total 22 6 16 44
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the base of the skull. Acquisition time was 5 min per bed position,
with a transmission time of 60 s each. Patients were scanned in
seven bed positions. PET images were reconstructed with and
without attenuation correction using a weighted iterative ordered
subsets expectation maximization algorithm (OSEM, two iterations,
eight subsets). In the final step, a three-dimensional isotropic gauss
filter was applied to a final image resolution with 8–9-mm full
width at half maximum.
Fig. 1. Posttreatment and pretreatment PET scan of a 51-year-old male with follicular non-Hodgkin lymphoma. Both interpreters
scored complete metabolic response on the isolated posttreatment PET scan. a Posttreatment PET scan: coronal images with an b
axial and c sagittal image at the level of the described lesion. d Pretreatment PET scan: coronal images with an e axial and f sagittal
image at the level of the described lesion. The pretreatment PET scan displaysmultiple regions with pathologic FDG uptake: multiple
regions above (neck and mediastinum) and below (intra abdominal and inguinal) diaphragm and diffuse bone marrow involvement.
With this knowledge, the initial interpretation of the posttreatment PET scan was changed to a positive posttreatment PET scan: In
the right inguinal region, there is increased FDG uptake. Without the pretreatment PET scan, this was considered physiologic.
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PET Analysis
Two nuclear medicine physicians with >5-year clinical PET
experience (MJH, JMHK) independently evaluated the PET scans.
First, they interpreted all 44 posttreatment PET scans, 3 weeks later
followed by another session in which the same posttreatment PET
scans were presented together with the baseline PET scans (paired
reading). The observers were aware that the patients had malignant
lymphoma but unaware of the type and grade of lymphoma and
results of baseline or posttreatment conventional staging. For each
scan, they analyzed 22 regions using a standardized form,
classifying FDG uptake as positive, negative, or equivocal. Criteria
for PET positivity were as follows: A region with FDG uptake
above background in a location incompatible with normal anatomy
or physiology was considered positive [7].
After evaluation of the forms of the posttreatment PET scans in
both sessions, the observers were requested to assign a consensus
score in case of discrepancies. Consensus was reached for the
Fig. 1. (continued).
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regions of the posttreatment PET without presentation of the
baseline PET, followed by the posttreatment PET in combination
with the baseline PET.
Besides this lesion-based analysis, the observers provided per
patient evaluations. In each patient, all scores of the 22 different
regions were taken together resulting in a negative posttreatment
PET scan (all regions negative, indicating complete metabolic
remission), or a positive posttreatment PET scan (≥1 positive
region). Patients with only equivocal scores, besides negative
scores, were classified as unclear.
Because both observers evaluated the PET scans without
clinical information, the positive or equivocal classified regions of
the posttreatment PET scans were compared with the initially
affected regions reported in the clinical database (baseline CT, PET
scan, bone marrow biopsy).
Statistical Analysis
We considered the consensus scores of the paired reading as the gold
standard for presence or absence of viable tumor after therapy. Tomeasure
the impact of adding a baseline PET scan as a function of sensitivity of
PET readings, the posttreatment PET results (isolated and paired reading)
were dichotomized by assigning the unclear classification to either the
PET-negative (complete responders) or to the PET-positive classification.
Sensitivity, specificity, positive predictive value, and negative predictive
value were determined for either strategy. To analyze interobserver
variability and agreement of isolated and combined baseline and
posttreatment PET readings, we used linear-weighted kappa (κw; SAS
9.1; SAS Institute, Cary, NC), considering kappa G0.20 as poor observer
agreement, 021–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as good,
and 0.81–1.00 as very good [11]. Ninety-five percent confidence intervals
of proportions were calculated with Confidence Interval Analysis 2.1.2.
Results
Subjects
We included 44 patients with a mean age of 56 years (SD
14), diagnosed with NHL in 35 (80%), and HD in nine
(20%) patients, further details are provided in Table 1. All
patients had FDG avid lymphoma at baseline and had been
clinically staged (including PET) according to the Ann
Arbor classification as stage 1 (n=3, 7%), stage 2 (n=15,
34%), stage 3 (n=16, 36%), and stage 4 (n=10, 23%).
Per Patient Analysis
For each patient, the initial stage of disease and type of
lymphoma as reported in the clinical digital database, the
scores of the “isolated” posttreatment PET scans, and the
paired posttreatment PET readings for either observer or
their consensus scores are provided in Appendix (Table 4).
In the consensus reading of the “isolated” posttreatment PET
scans, 24 PET scans were classified as negative, six as unclear,
Table 3. Per region analysis of the agreement of isolated posttreatment and reference PET classifications (a), as a function of PET positivity criteria (b), and
observer agreement (c)
(a)
Consensus-isolated posttreatment PET Consensus-paired reading (reference standard)
Negative Unclear Positive Total
Negative 909 5 9 923
Unclear 6 1 3 10
Positive 5 1 29 35
Total 920 7 41 968
(b)
Conservative: consensus-isolated posttreatment PET Conservative: consensus-paired reading (reference standard)
Negative Positive Total
Negative 921 12 933
Positive 6 29 35
Total 927 41 968
Sensitive: consensus-isolated posttreatment PET Sensitive: consensus-paired reading (reference standard)
Negative Positive Total
Negative 909 14 923
Positive 11 34 45
Total 920 48 968
(c)
Observer 1 isolated posttreatment PET Observer 1 posttreatment PET (paired reading)
Negative Unclear Positive Total
Negative 902 3 12 917
Unclear 9 1 3 13
Positive 17 2 19 38
Total 928 6 34 968
Observer 2 isolated posttreatment PET Observer 2 posttreatment PET (paired reading)
Negative Unclear Positive Total
Negative 898 9 6 913
Unclear 6 2 5 13
Positive 10 2 30 42
Total 914 13 41 968
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and 14 as positive. In the consensus reading of the paired
reading, 25 posttherapy PET scans were classified as negative,
three as unclear, and 16 as positive (Table 2). The consensus
scores of the isolated posttreatment PET scans vs paired
reference standard were concordant in 29/44 cases (66%, 95%
CI 54–77%) resulting in a good correlation (κw=0.73, 95% CI
0.64–0.83, pG0.0001). The proportion of “unclear” readings
was 6.8% in the paired reading vs 13.6% in the isolated reading.
Adding the baseline PET scan altered the PET classification in
15 cases but in either direction of suspicion: in eight patients the
level of suspicion increased, in seven decreasing (Table 2a). In
six cases (13.6%) the conclusion was opposite, with three false
positive and three false negative (Fig. 1) isolated PET readings.
Dichotomization did not clearly affect the results with accu-
racies of 75% (95% CI 63–84%) and 77% (95% CI 65–86%)
for sensitive and conservative reading strategies, respectively
(kappa’s: 0.49, 95% CI 0.28–0.71 vs 0.50, 95% CI 0.26–0.73,
respectively). False positivity rates of the isolated posttreatment
PET interpretations prevailed in 4/14 (29%, 95% CI 14–51%)
and 6/20 (30%, 95%CI 16–48%) for conservative and sensitive
readings, respectively (Table 2b).
The interobserver agreement of paired baseline and
posttreatment evaluations was similar compared to the
isolated PET evaluations (linear weighted kappa’s: 0.64,
95% CI 0.46–0.82 vs 0.67, 95% CI 0.51–0.83, respectively).
Per Lesion Analysis
As expected, the large majority of regions were FDG negative: in
the consensus setting, 95% of both isolated posttreatment scans
and paired readings (Table 3a); of the nonnegative readings, 22%
and 17%were classified as “unclear,” respectively (NS). Twenty-
four of the isolated posttherapy PET classifications altered after
addition of the baseline scan (similar to the patient-based
analysis), and the change was in either direction of suspicion
(12 towards lower level). Dichotomization yielded kappa’s of
0.75 (95% CI 0.66–0.85) and 0.71 (95% CI 0.63–0.81) for
conservative and sensitive reading strategies, respectively. The
false positivity rates of isolated PET readings were 17% (95 %CI
9–30%) and 24% (95% CI 16–36%) with conservative and
sensitive readings, respectively. The interobserver agreement for
the per lesion evaluation of the isolated posttreatment PET scans
was good (κw=0.71, 95% CI 0.61–0.81, pG0.0001). Adding the
baseline PET information did not further improve the observer
agreement (κw=0.66, 95% CI 0.52–0.75, pG0.0001). Discrepant
lesional scores were randomly divided over the 22 different
regions, the number of different scores ranging from 1 to 7 for
each region in 20 of 22 regions.
Discussion
The addition of baseline to posttreatment PET evaluation affected
the classification of metabolic response in 34% of malignant
lymphoma patients treated with first-line chemotherapy. In one
out of seven patients, addition of the baseline PET lead to
opposite conclusions (95% CI 4–14). False positivity was
reduced by adding the baseline scan information, but the effect
on false negativity was similar. In addition, the amount of unclear
classifications reduced (50%) after paired reading. Observer
agreement did not improve upon adding the baseline PET data.
In malignant lymphoma, baseline PET information is
essential to be able to assess response in lymphoma types with
variable FDG avidity. In routinely FDG-avid lymphoma,
baseline scans are recommended but not mandatory [8]. The
intrinsic paradox flows from a lack of evidence, primarily at the
level of effectiveness. Obvious disadvantages of routine base-
line scanning are costs and unnecessary radiation (typically
about 3.5 mSv) added by FDG to the standard CTwork-up [12,
13]. In case of adding low-dose CT to PET, augmented with
another 2–3 mSv [14]. Even though diagnostic CT (typically
extending from neck to perineum in these patients) yields most
of the radiation dose, adding PET should be justified by an
impact on disease classification.
Our study has some limitations. First, PET scans in this study
were performed with a stand-alone PET scanner rather than with
PET-CT. Second, the observers were blinded for type and grade
of lymphoma, pretreatment, or posttreatment situation and CT
findings. An argument favoring interpreting diagnostic tests
with clinical information is that the accuracy of the read may be
improved by the additional information. It could be argued that
the added value of the pretreatment PET scan may have been
less, when this information had been provided. An argument
favoring interpreting diagnostic tests without clinical informa-
tion is that it may bias the reading and that clinical information
should be incorporated into decision-making only after an
unbiased read [15]. In three patients, one region which was
initially not affected according to the clinical digital database
was classified as equivocal in the first session. After paired-
reading, these scores were changed into negative. In this
situation the pretreatment scan provided the same information
as the knowledge of the initial clinical information and instead
of 34% (15/44), 27% (12/44) of the overall results differed.
In conclusion, without any other clinical information, a
pretreatment PET facilitates and changes the interpretation
of a posttreatment PET in a third of the patients, resulting in
both upgrading and downgrading of the posttreatment
situation of a malignant lymphoma patient. Adding a
baseline PET scan did not improve observer agreement. If
these results are confirmed for PET/CT systems, they favor
the addition of baseline PET to the current work-up of
patients with malignant lymphoma.
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Table 4. Results per case of the PET evaluation
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10 4, NHL; diffuse large B cell lymphoma − − − − − − No
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32 3, NHL; follicular − − − − − − No
33 2, NHL; follicular − − − − − − No
34 2, HD; nodular sclerosis − − − − − − No
35 4, HD; nodular sclerosis U − − − − − No
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44 2, NHL; diffuse large B cell lymphoma − − − − − − No
aPost: per patient evaluation of the posttreatment PET scan without knowledge of the pretreatment PET scan
bPost and pre: per patient evaluation of the posttreatment PET scan after visualization of the pretreatment PET scan, i.e., paired reading
cDifference: if there is a difference in interpretation of the posttreatment PET with and without the knowledge of the pretreatment PET
dUnclear: when one or more regions are scored equivocal and all other regions are classified negative in the PET scan, it is not possible to determine whether
the scan is positive or negative, and the conclusion is unclear
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